Journal of Korean Medicine Rehabilitation (한방재활의학과학회지)

The society of Korean Medicine Rehabilitation (한방재활의학과학회)
권호 표지
DOI QR코드

DOI QR Code

The Inhibitory Effect of ChondroT on Indomethacin-Induced Gastric Mucosal Injury in Rats

Indomethacin으로 유발된 흰쥐의 위장장애에 ChondroT가 미치는 영향

  • Kim, Joo-Il (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongshin University) ;
  • Kim, Sun-Gil (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongshin University) ;
  • Kim, Ji-Hoon (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongshin University) ;
  • Yoon, Chan-Suk (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongshin University) ;
  • Choi, Ji-Min (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongshin University) ;
  • Choi, Chan-Hun (Department of Physiology of Korean Medicine, College of Korean Medicine, Dongshin University) ;
  • Kim, Seon-Jong (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongshin University)
  • 김주일 (동신대학교 한의과대학 한방재활의학과교실) ;
  • 김선길 (동신대학교 한의과대학 한방재활의학과교실) ;
  • 김지훈 (동신대학교 한의과대학 한방재활의학과교실) ;
  • 윤찬석 (동신대학교 한의과대학 한방재활의학과교실) ;
  • 최지민 (동신대학교 한의과대학 한방재활의학과교실) ;
  • 최찬헌 (동신대학교 한의과대학 생리학교실) ;
  • 김선종 (동신대학교 한의과대학 한방재활의학과교실)
  • Received : 2020.06.11
  • Accepted : 2020.06.24
  • Published : 2020.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives The aim of this study was to investigate the inhibitory effect of ChondroT in indomethacin-induced gastric mucosal injury rat model. Methods Sprague-Dawley rats were randomly assigned to intact, control Joins, Celebrex, ChondroT50 and ChondroT200. Indomethacin (25 mg/kg) was used to induce damage to the gastric mucosal injury. ChondroT was administered by orally to inhibit the indomethacin-induced gastric mucosal injury. At the end of the experiment, pH level in stomach, stomach contents volume, tumor necrosis factor-α (TNF-α) level, interleukin-1β (IL-1β) level, prostaglandin E2 (PGE2) level, myeloperoxidase (MPO) activity, erythrocytes, and thrombocytes were measured. Ophthalmologic and histopathological examination was also analyzed. Results pH level in stomach and Stomach contents volume had no difference between Control, PC-Joins, PC-Cele, ChondroT50 and ChondroT200 group. TNF-α level was decreased in PC-Joins, PC-Cele, ChondroT50 and ChondroT200 group and there were no significant difference. IL-1β level was decreased in PC-Joins group and ChondroT200 group compared to control group. PGE2 level had no significant difference between Control, PC-Joins, PC-Cele, ChondroT50 and ChondroT200 group. MPO level and complete blood count level were decreased in PC-Joins, PC-Cele, ChondroT50 and ChondroT200. Symptom score of ophthalmologic examination was decreased in ChondroT50 and ChondroT200 group compared to control group. Conclusion Based on these results, It could be suggested that ChondroT was effective in reducing damage to the gastric mucosal injury. And further study is needed to conduct a rigorous clinical research.

Keywords

References

  1. Richmond J, Hunter D, Irrgang J, Jones MH, Levy B, Marx R, Snyder-Mackler L, Watters WC 3rd, Haralson RH 3rd, Turkelson CM, Wies JL, Boyer KM, Anderson S, St Andre J, Sluka P, McGowan R. Treatment of osteoarthritis of the knee (nonarthroplasty). J Am Acad Orthop Surg. 2009;17:591-600. https://doi.org/10.5435/00124635-200909000-00006
  2. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL, Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, Woolf A, March L. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323-30. https://doi.org/10.1136/annrheumdis-2013-204763
  3. Busija L, Bridgett L, Williams SRM, Osborne RH, Buchbinder R, March L, Fransen M. Osteoarthritis. Best Pract Res Clin Rheumatol. 2010;24:757-68. https://doi.org/10.1016/j.berh.2010.11.001
  4. Felson DT, Zhang Y. An update on the epidemiology od knee and hip osteoarthritis with a view to prevention. Am Coll Rheumatol. 1998;41:1343-55.
  5. Duncan R, Peat G, Thomas E, Hay EM, Croft P. Incidence, progression and sequence of development of radiographic knee osteoarthritis in a symptomatic population. Ann Rheum Dis. 2011;70:1944-8. https://doi.org/10.1136/ard.2011.151050
  6. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26:355-69. https://doi.org/10.1016/j.cger.2010.03.001
  7. The Korean Orthopaedic Association. Orthopaedics. 7th ed. Seoul:ChoiSin medical Publishing Co. 2013:317-27.
  8. Dekker J. Exercise and physical functioning in osteoarthritis. New York, NY:Springer. 2014.
  9. Hunter DJ, Lo GH. The management of osteoarthritis: an overview and call to appropriate conservative treatment. Rheum Dis Clin N Am. 2008;34:689-712. https://doi.org/10.1016/j.rdc.2008.05.008
  10. Jordan KM. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55. https://doi.org/10.1136/ard.2003.011742
  11. Harvey WF, Hunter DJ. The role of analgesics and intra-articular injections in disease management. Rheum Dis Clin N Am. 2008;34:777-88. https://doi.org/10.1016/j.rdc.2008.05.006
  12. Knee Surgery & Related Research. Guidelines for the treatment of osteoarthritis of the knee. Knee Surg Relat Res. 2010;22:69-74.
  13. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-62. https://doi.org/10.1016/j.joca.2007.12.013
  14. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594-606. https://doi.org/10.1053/gast.2001.21907
  15. Kelton JG, Blajchman MA. Prostaglandin I2 (prostacycin). CMA Journal. 1980;122:175-9.
  16. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44:1-10. https://doi.org/10.1007/BF01630479
  17. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1707-9. https://doi.org/10.1056/NEJMp048288
  18. Bae KJ. Anti-osteoarthritic effects of ChondroT in a MIA-induced rat model [dissertation]. Naju:Dongshin University; 2016.
  19. Kim HA. Pharmacological treatment of osteoarthritis. J Korean Orthop Res Soc. 2010;13:16-22.
  20. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002;89:18-25. https://doi.org/10.1016/S0002-9149(02)02233-6
  21. Won JY, Jeong JW, Na CS, Kim SJ. Analgesic effects of ChondroT in collagenase-induced osteoarthritis rat model. J Korean Med Rehabil. 2016;26:17-30. https://doi.org/10.18325/jkmr.2016.26.3.17
  22. Bae KJ, Jeong JW, Song MY, Kim TG, Kim SJ. The domestic trends of osteoarthritis-related research on each constituent herb of ChondroT - focused on the Journal of Korean Medicine. J Korean Med Rehabil. 2015;25:55-63. https://doi.org/10.18325/jkmr.2015.25.4.55
  23. Park JU, Kim SJ, Na CS, Choi CH, Seo CS, Son JK, Kang BY, Kim YR. Chondroprotective and anti-inflammatory effects of ChondroT, a new complex herbal medication. BMC Complement Altern Med. 2016;16:213-23. https://doi.org/10.1186/s12906-016-1211-0
  24. Bae KJ, Jeong JW, Choi CH, Won JY, Kim TG, Kim YR, Na CS, Kim SJ. Antiosteoarthritic effects of ChondroT in a rat model of monosodium iodoacetate-induced osteoarthritis. Evid Based Complement Alternat Med. 2018;2018:1-11.
  25. Jeong JW, Bae KJ, Kim SG, Kwak DW, Moon YJ, Choi CH, Kim YR, Na CS, Kim SJ. Anti-osteoarthritic effects of ChondroT in a rat model of collagenase-induced osteoarthritis. BMC Complement Altern Med. 2018;18:131-40. https://doi.org/10.1186/s12906-018-2149-1
  26. Dequeker J, Luyten FP. The history of osteoarthritisosteoarthrosis. Ann Rheum Dis. 2008;67:5-10. https://doi.org/10.1136/ard.2007.079764
  27. Nakasato Y, Yung RL. Geriatric rheumatology. New York, NY:Springer. 2011.
  28. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115-26. https://doi.org/10.1016/S0140-6736(11)60243-2
  29. Lee EJ, Oh MS. effects of keonbodan on MIA-Induced osteoarthritis in rat. J Korean Med Rehabil. 2014;24:51-64.
  30. Neogi T. Clinical significance of bone changes in osteoarthritis. Ther Adv Musculoskel Dis. 2012;4:259-67. https://doi.org/10.1177/1759720X12437354
  31. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis. 2005;64:1539-41. https://doi.org/10.1136/ard.2005.039263
  32. Lee HS. Prevalence of osteoarthritis and related risk factors in the elderly: data from the fifth Korea national health and nutrition examination survey (KNHANES V), 2010-2012. J Korean Diet Assoc. 2014;20:99-109. https://doi.org/10.14373/JKDA.2014.20.2.99
  33. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic NSAIDs use. Am J Gastroenterol. 1987;82:1153-8.
  34. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 1996;6:489-504. https://doi.org/10.1016/S1052-5157(18)30351-9
  35. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247. https://doi.org/10.1001/jama.284.10.1247
  36. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-8. https://doi.org/10.1056/NEJM200011233432103
  37. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000;119:521-35. https://doi.org/10.1053/gast.2000.9561
  38. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-42. https://doi.org/10.1161/CIRCULATIONAHA.106.181424
  39. NICE (National Institute for Health and Clinical Excellence). NSAIDs prescribing issues [Internet] 2015 [cited 2020 Jun 10]. Available from: URL: http://cks.nice.org.uk/nsaids-prescribing-issues.
  40. Park YB. Cyclooxygenase-2 inhbitors and cardiovascular risk. Hanyang Med Rev. 2005;25:67-72.
  41. Son CY, Baek IH, Song GY, Kang JS, Kwan KI. Pharmacological effect of decursin and decursinol angelate from Angelica gigas Nakai. J Pharm Soc Korea. 2009;53:303-13.
  42. Choi W, Choi CH, Kim YR, Kim SJ, Na CS, Lee H. HerDing: herb recommendation system to treat diseases using genes andchemicals. Database (Oxford). 2016;2016:doi:10.1093/database/baw011.
  43. Kim SG, Jeong JW, Lim YH, Kim JH, Na CS, Kim SJ. A study on the anti-condensing effect of ChondroT components. J Korean Med Rehabil. 2018;28:47-60. https://doi.org/10.18325/jkmr.2018.28.2.47
  44. Lim YH, Jeong JW, Kim SG, Kim JH, Kim SJ. DRF and single dose oral toxicity study of ChondroT in rat. J Korean Med Rehabil. 2018;28:61-72. https://doi.org/10.18325/jkmr.2018.28.1.61
  45. Kwan SW. Research and development trends for new natural products (oriented by development research). Biotech Information Portal. 2012;59.
  46. Koki AT, Masferrer JL. Celecoxib: A specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9:28-35. https://doi.org/10.1177/107327480200902s04
  47. Kang MH, Tae IW, Cho SW. The studies on antiulcer effect of herbal medicines against experimental gastric ulcer. J Korea Acad-Ind Coop Soc. 2009;10:607-11. https://doi.org/10.5762/KAIS.2009.10.3.607
  48. Oh TY, Ryu BK, Ko JI, Ahn BO, Kim SK, Kim WB, Lee EB, Jin JH, Hahm KB. Protective effect of DA-9601, an extract of Artemisiae Herba, against naproxen-induced gastric damage in arthritic rats. Arch Pharm Res. 1997;20:414-9. https://doi.org/10.1007/BF02973932
  49. Ryu MS, Yun YC, Kim JH. The effect of Angelica gigas NAKAI pharmacopuncture at ST36 and BL23 on Freund's adjuvant arthritis in rats. J Korean Acupuncture Moxibustion Soc. 2010;27:25-34.
  50. Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 2007;38:151-6. https://doi.org/10.1016/j.cyto.2007.06.001
  51. Kung SE, Oh MS. Effects of Sayeok-tang on papain-induced osteoarthritis in mice. Korean J Orient Physiol Pathol. 2013;27:212-24.
  52. Kim DH, Kang SI, Song MY, Choi JB, Bae KJ, Han JS, Yang MS, Shin YJ. Effect of Bangkeehwangkeetang treatment on the monosodium iodoacetate-induced osteoarthritis in rats. J Korean Med Rehabil. 2014;24:15-29.
  53. Huang J, Milton A, Arnold RD, Huang H, Smith F, Panizzi JR, Panizzi P. Methods for measuring myeloperoxidase activity toward assessing inhibitor efficacy in living systems. J Leukoc Biol. 2016;99:541-8. https://doi.org/10.1189/jlb.3RU0615-256R
  54. Kim DH, Jeong SH, Seo IB, Kim SJ. Suppression effects of Sopunghwalhyeol-tang (Shufenghuoxie-tang) on the monosodium iodoacetate-induced osteoarthritis in rats. J Korean Med Rehabil. 2011;21:57-77.
  55. Feldman AT, Wolfe D. Tissue processing and Hematoxylin and Eosin staining. In: Day CE, ed. Histopathology. New York, NY:Springer. 2014:31-43.